HBM Healthcare Investments' Swixx BioPharma Expands in Latin America

Swixx BioPharma, the largest investment in HBM Healthcare Investments' private equity portfolio, announced its expansion into Latin America by acquiring Laboratorios Biopas Group.

Biopas, with USD 220 million in sales and over 300 employees, is a leading biopharmaceutical marketing and distribution company in Latin America. The acquisition extends Swixx BioPharma’s reach, covering therapeutic areas in Neurology, Oncology, Gastroenterology, and Rare Diseases. Biopas operates from Bogota, Colombia, and is present in 20 countries, including major markets like Argentina, Brazil, Chile, Colombia, and Mexico.

This move follows Swixx BioPharma's Middle East expansion in September 2023. The acquisition aims to make Swixx a global partner for biopharma companies seeking indirect market entry. The transaction will be financed through cash, bank loans, and equity, with regulatory approvals expected by mid-2024. HBM Healthcare has held a 25% stake in Swixx BioPharma since 2017.